Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$44.25 -0.4%	$38.61	$30.04 ▼ $63.68	$3.82B	1.75	1.78 million shs	3.05 million shs
MMSI Merit Medical Systems	$91.98 -1.0%	$94.53	$82.04 ▼ $111.45	$5.44B	0.66	534,892 shs	960,835 shs
NTRA Natera	$171.86 +0.5%	$157.00	$92.14 ▼ $183.00	$23.47B	1.74	1.41 million shs	1.52 million shs
PINC Premier	$22.06 -0.9%	$21.90	$17.23 ▼ $23.56	$1.82B	0.57	1.22 million shs	5.07 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	-0.41%	+6.99%	+19.63%	+7.35%	-26.94%
MMSI Merit Medical Systems	-1.04%	-1.06%	-4.67%	-9.54%	+13.08%
NTRA Natera	+0.51%	+3.94%	+13.75%	+13.70%	+59.14%
PINC Premier	-0.94%	-2.26%	-4.34%	+18.92%	+21.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRSP CRISPR Therapeutics	3.2831 of 5 stars	4.2	2.0	0.0	0.0	2.7	2.5	0.6
MMSI Merit Medical Systems	4.1032 of 5 stars	3.5	1.0	0.0	3.8	2.3	2.5	1.3
NTRA Natera	1.0718 of 5 stars	1.5	2.0	0.0	0.0	2.6	2.5	0.6
PINC Premier	2.1974 of 5 stars	1.0	3.0	2.5	0.0	2.5	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRSP CRISPR Therapeutics	2.47	Hold	$69.53	57.14% Upside
MMSI Merit Medical Systems	3.00	Buy	$109.11	18.62% Upside
NTRA Natera	3.00	Buy	$184.63	7.43% Upside
PINC Premier	2.00	Hold	$22.20	0.63% Upside

Current Analyst Ratings Breakdown

Latest PINC, MMSI, NTRA, and CRSP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/23/2025	MMSI Merit Medical Systems	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$106.00 ➝ $110.00
5/21/2025	CRSP CRISPR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00 ➝ $86.00
5/21/2025	MMSI Merit Medical Systems	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$108.00 ➝ $112.00
5/21/2025	MMSI Merit Medical Systems	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$106.00 ➝ $108.00
5/21/2025	PINC Premier	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$19.00 ➝ $24.00
5/20/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00 ➝ $81.00
5/20/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00 ➝ $65.00
5/15/2025	MMSI Merit Medical Systems	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$100.00 ➝ $108.00
5/15/2025	NTRA Natera	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$205.00 ➝ $210.00
5/15/2025	PINC Premier	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$19.00 ➝ $22.00
5/9/2025	CRSP CRISPR Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$56.00 ➝ $42.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRSP CRISPR Therapeutics	$37.31M	102.42	N/A	N/A	$22.64 per share	1.95
MMSI Merit Medical Systems	$1.36B	4.01	$5.61 per share	16.41	$23.67 per share	3.89
NTRA Natera	$1.70B	13.83	N/A	N/A	$9.05 per share	18.99
PINC Premier	$1.35B	1.35	$3.64 per share	6.06	$18.68 per share	1.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRSP CRISPR Therapeutics	-$366.25M	-$4.52	N/A	N/A	N/A	-1,023.64%	-20.08%	-17.13%	8/4/2025 (Estimated)
MMSI Merit Medical Systems	$120.36M	$2.04	45.09	24.53	3.03	8.81%	15.52%	8.72%	7/30/2025 (Estimated)
NTRA Natera	-$190.43M	-$1.47	N/A	N/A	N/A	-10.36%	-18.29%	-11.68%	8/14/2025 (Estimated)
PINC Premier	$119.54M	$0.57	38.70	16.59	N/A	5.68%	8.79%	4.86%	8/19/2025 (Estimated)

Latest PINC, MMSI, NTRA, and CRSP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	NTRA Natera	-$0.59	-$0.50	+$0.09	-$0.50	$446.68 million	$501.83 million
5/6/2025	Q1 2025	CRSP CRISPR Therapeutics	-$1.27	-$1.58	-$0.31	-$1.58	N/A	N/A
4/24/2025	Q1 2025	MMSI Merit Medical Systems	$0.75	$0.86	+$0.11	$0.49	$352.57 million	$355.35 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
MMSI Merit Medical Systems	N/A	N/A	N/A	N/A	N/A
NTRA Natera	N/A	N/A	N/A	N/A	N/A
PINC Premier	$0.84	3.81%	N/A	147.37%	N/A

Latest PINC, MMSI, NTRA, and CRSP Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/24/2025	PINC Premier	quarterly	$0.21	4.2%	5/30/2025	6/1/2025	6/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRSP CRISPR Therapeutics	N/A	15.64	15.64
MMSI Merit Medical Systems	0.51	4.87	3.26
NTRA Natera	N/A	3.87	3.74
PINC Premier	N/A	0.65	0.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRSP CRISPR Therapeutics	69.20%
MMSI Merit Medical Systems	99.66%
NTRA Natera	99.90%
PINC Premier	74.41%

Insider Ownership

Company	Insider Ownership
CRSP CRISPR Therapeutics	4.30%
MMSI Merit Medical Systems	3.20%
NTRA Natera	7.60%
PINC Premier	0.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRSP CRISPR Therapeutics	473	86.36 million	82.65 million	Optionable
MMSI Merit Medical Systems	7,400	59.10 million	57.21 million	Optionable
NTRA Natera	4,434	136.55 million	126.17 million	Optionable
PINC Premier	2,900	82.34 million	81.55 million	Optionable

PINC, MMSI, NTRA, and CRSP Headlines

Recent News About These Companies

GAMMA Investing LLC Raises Holdings in Premier, Inc. (NASDAQ:PINC)

June 20 at 3:13 AM | marketbeat.com

Exchange Traded Concepts LLC Acquires 16,663 Shares of Premier, Inc. (NASDAQ:PINC)

June 18 at 3:58 AM | marketbeat.com

Ritholtz Wealth Management Purchases New Position in Premier, Inc. (NASDAQ:PINC)

June 18 at 3:50 AM | marketbeat.com

1 Small-Cap Stock to Research Further and 2 to Keep Off Your Radar

June 17, 2025 | msn.com

Premier, Inc. (NASDAQ:PINC) Shares Sold by Rhumbline Advisers

June 14, 2025 | marketbeat.com

Premier African Minerals shares slump 30% after fresh fundraising

June 11, 2025 | proactiveinvestors.co.uk

OLD National Bancorp IN Makes New $234,000 Investment in Premier, Inc. (NASDAQ:PINC)

June 11, 2025 | marketbeat.com

Health-care exec leads 2025 class of CFO of the Year honorees

June 10, 2025 | bizjournals.com

Wedge Capital Management L L P NC Boosts Position in Premier, Inc. (NASDAQ:PINC)

June 10, 2025 | marketbeat.com

42,096 Shares in Premier, Inc. (NASDAQ:PINC) Bought by Two Sigma Investments LP

June 7, 2025 | marketbeat.com

Premier, Inc. (NASDAQ:PINC) Director Sells $26,185.11 in Stock

June 6, 2025 | insidertrades.com

John T. Bigalke Sells 1,137 Shares of Premier, Inc. (NASDAQ:PINC) Stock

June 5, 2025 | marketbeat.com

Insider Selling: Premier, Inc. (NASDAQ:PINC) Director Sells 2,000 Shares of Stock

June 3, 2025 | marketbeat.com

1 Mooning Stock on Our Buy List and 2 to Be Wary Of

June 3, 2025 | msn.com

Premier, Inc. (NASDAQ:PINC) Director Helen M. Boudreau Sells 2,000 Shares

June 3, 2025 | insidertrades.com

Universal Beteiligungs und Servicegesellschaft mbH Makes New $4.29 Million Investment in Premier, Inc. (NASDAQ:PINC)

June 2, 2025 | marketbeat.com

Premier, Inc. (NASDAQ:PINC) Receives Average Rating of "Hold" from Brokerages

June 2, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Holdings in Premier, Inc. (NASDAQ:PINC)

June 1, 2025 | marketbeat.com

Nuveen Asset Management LLC Sells 21,079 Shares of Premier, Inc. (NASDAQ:PINC)

June 1, 2025 | marketbeat.com

Premier American Uranium Positioned for U.S. Nuclear Resurgence Amid Transformational Policy Shift

May 27, 2025 | globenewswire.com

Millennium Management LLC Grows Holdings in Premier, Inc. (NASDAQ:PINC)

May 27, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Palantir Scores First $1 Billion Contract; Is It Priced In?
By Chris Markoch | May 27, 2025
View Palantir Scores First $1 Billion Contract; Is It Priced In?
BigBear.ai: Risky AI Stock or Defense Tech Opportunity?
By Jeffrey Neal Johnson | May 28, 2025
View BigBear.ai: Risky AI Stock or Defense Tech Opportunity?
Astronics Corporation: Up 100% YTD in May and Heading Higher
By Thomas Hughes | May 28, 2025
View Astronics Corporation: Up 100% YTD in May and Heading Higher
Science Applications International Is a Wicked Hot Buy in June
By Thomas Hughes | June 9, 2025
View Science Applications International Is a Wicked Hot Buy in June
Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer
By Jeffrey Neal Johnson | June 19, 2025
View Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer

PINC, MMSI, NTRA, and CRSP Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

$44.25 -0.18 (-0.41%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$44.26 +0.02 (+0.03%)

As of 06/20/2025 07:52 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Merit Medical Systems NASDAQ:MMSI

$91.98 -0.97 (-1.04%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$91.95 -0.03 (-0.03%)

As of 06/20/2025 05:28 PM Eastern

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate structures; gastroenterology products, such as covered esophageal stents, syringe and gauges, and balloon dilators; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.

Natera NASDAQ:NTRA

$171.86 +0.88 (+0.51%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$171.86 +0.00 (+0.00%)

As of 06/20/2025 06:59 PM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Premier NASDAQ:PINC

$22.06 -0.21 (-0.94%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$21.92 -0.15 (-0.66%)

As of 06/20/2025 04:53 PM Eastern

Premier, Inc., together with its subsidiaries, operates as a healthcare improvement company in the United States. It operates in two segments, Supply Chain Services and Performance Services. The Supply Chain Services segment offers its members with an access to a range of products and services, including medical and surgical products, pharmaceuticals, laboratory supplies, capital equipment, information technology, facilities and construction, and food and nutritional products, as well as purchased services, such as clinical engineering and workforce solutions. This segment also provides the ASCENDrive programs for members to receive group purchasing programs, tiers, and prices; SURPASS Performance Group services; and STOCKD, an e-commerce platform, as well as direct sourcing business; SaaS informatics products; supply chain co-management services; purchased services contracts; direct sourcing solutions; and supply chain resiliency programs. The Performance Services segment provides technology and services platform with offerings that help optimize performance in three main areas, including clinical intelligence, margin improvement, and value-based care under the PINC AI brand; third party administrator services and management of health benefit programs under the Contigo Health brand; and digital invoicing and payables services that offers financial support services to healthcare product suppliers and service providers under the Remitra brand. The company was incorporated in 2013 and is based in Charlotte, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time